Supplementary Information
Supplementary materials and methods
RNA sequencing
Total cellular RNA was isolated using the ISOLATE II RNA Mini Kit (BIO-52073) and 20 μl aliquots dried by vacuum concentration for 30 min at room temperature in the presence of RNAstable (Biomatrica 93221-001). RNAseq was then performed commercially using the services of BGI (China). Briefly, rRNA was removed using the Ribo-Zero rRNA Removal Kit prior to strand-specific library construction. Quality control assessment and quantification of sample libraries were performed using an Agilent 2100 Bioanalyzer and ABI StepOnePlus Real-Time PCR System before library sequencing using an Illumina HiSeqTM 2000 in 100 bp single read mode. 
In vitro transcription
The DNA template used for in vitro synthetization of biotinylated OVAAL was generated by PCR amplification. Forward primer used contained the T7 RNA polymerase promoter sequence allowing for subsequent in vitro transcription. PCR products were purified using DNA Gel Extraction kit (AxyPrep). In vitro transcription was then performed using T7-Flash Biotin-RNA Transcription Kit (Epicentre) according to the instructions provided by the manufacturer.
Ubiquitination assay
Ubiquitination assays were performed as per published methods (1) . In brief, cell lysates were boiled at 95 °C for 10 min before shearing released DNA by sonication. After diluting samples, the cell extracts were then incubated with A/G agarose beads for 3 h, washed, and subjected to immunoblotting analysis.
Cytosolic/nuclear fractionation
Cells were incubated with hypotonic buffer (25 mM Tris-HCl, PH 7.4, 1 mM MgCl2, 5 mM KCl) on ice for 5 min. An equal volume of hypotonic buffer containing 1% NP-40 was then added, and the sample was left on ice for another 5 min. After centrifugation at 5,000 g for 5 min, the supernatant was collected as the cytosolic fraction. The pellets were resuspended in nuclear resuspension buffer (20 mM HEPES, pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF) and incubated at 4 °C for 30 min. The nuclear fraction was collected after removal of insoluble membrane debris by centrifugation at 12,000 g for 10 min.
Colony formation assay
Cells were transduced with the control shRNA or OVAAL shRNA. Twenty-four hours later, 1 × 10 3 cells were cultured in a six-well plate. Two weeks later, cells were fixed, stained with crystal violet, and photographed.
Three-dimensional culture
Three-dimensional culture was performed using the hanging drop technique, as previously described (2) . Cells were stained with calcein AM (living cell stain) and ethidium homodimer-1 (dead cell stain) (Life Technologies, Scoresby, Victoria, Australia) for 30 min, followed by treatment.
Cell viability
The CellTiter-Glo Luminescent Cell Viability Assay kit (Promega) was used according to the manufacturer's instructions. Briefly, cells were seeded at 5 × 10 3 /well in 96-well plates overnight before treatment as desired. CellTiter-Glo Reagent (100 μl) was added and incubated for 10 min before recording luminescence on a Synergy 2 multidetection microplate reader (BioTek)(3).
Senescence
Senescence-associated β-galactosidase (SA-β-gal) staining was performed using a Senescence Detection Kit according to the manufacturer's instructions (Beyotime C0602). Percentages of SA-β-gal-positive cells were calculated from five random fields under a light microscope (10 × objective).
Luciferase reporter assays
Luciferase reporter assays were performed according to the manufacturer's introduction (Promega). Cells were transfected with the pGL3-based constructs containing OVAAL promoter together with Renilla luciferase plasmids. Twenty-four hours later, firefly and Renilla luciferase activity was examined by Dual-Luciferase® Reporter Assay System (Promega) and Renilla activity was used to normalize firefly activity.
Western Blotting
Cells were harvested and washed twice with cold PBS. After adding lysis buffer II (10 mM TrisHCl (pH7.6), 140 mM NaCl, 0.5 mM CaCl2, 0.5 mM MgCl2, 0.02% NaN3, 1% Triton X-100 and proteinase inhibitor cocktail (Sigma-Aldrich)), samples were lysed for 30 min on ice and vortexed every 10 min followed by centrifugation at 4 °C, 13,000 rpm for 30 min. Thirty to fifty micrograms of whole-cell protein were subjected to sodium dodecyl polyacrylamide gel electrophoresis (SDS-PAGE) and subsequently transferred onto nitrocellulose membranes. Membranes were blocked with 5% non-fat milk at room temperature for 1 h or at 4 °C overnight and then incubated with antibody. Images were captured by the Image Reader.
Northern blotting
Total RNA was extracted and resolved on 1% denaturing agarose gels run at 50V for 2 h. After electrophoresis, samples were transferred to nylon membranes (Hybond-N; GE Healthcare)
followed by UV crosslinking. The prehybridization/hybridization procedures were performed according to the manufacturer's instructions before the application of in vitro transcribed Digoxigenin-labeled antisense probes against OVAAL (DIG Northern Starter Kit; Roche). After hybridization, samples were incubated with anti-digoxin antibodies for 1 h at room temperature and binding of the probes visualized using ECL (Image Quant LAS-4000 mini; GE Fujifilm).
Fluorescence in situ hybridization
Antisense probes targeting OVAAL were transcribed in vitro and fluorescently labeled using the Nucleic Acid Labeling Kit (Life technologies, USA). Cells for analysis were fixed in 4%
paraformaldehyde at room temperature for 15 min and after rinsing with PBS, permeabilized in
TritonX-100/DEPC/PBS for 5 min. Probes were then diluted in hybridization buffer (4 × SSC, 10%
dextran sulfate, 50% deionized-formamide in DEPC-H2O) and denatured at 80 °C for 10 min before addition to the cells overnight at 37 °C. The next day, samples were washed three times with buffer (2 × SSC, 50% deionized-formamide in DEPC-H2O), cell nuclei counterstained with Hoechst and samples mounted onto glass slides.
Flow cytometric analysis
Annexin V staining in combination with viable dye exclusion (propidium iodide; PI) was used to V binding buffer added after 15 min incubation in the dark. Samples were subjected to flow cytometry analysis within 1 h using a BD FACSCanto II instrument (BD). Alternatively, cell cycle analyses were conducted using PI staining after cell permeabilization as previously described (4).
Tumor xenograft mouse model
HCT116 cells expressing the control or OVAAL shRNA were subcutaneously injected into the dorsal flanks of 4-week-old male nude mice (Shanghai SLAC Laboratory Animal Co. Ltd. 
Fig S2. OVAAL protects cancer cells from venetoclax (ABT-199) and A-1331852, selective inhibitors of Bcl-2 and Bcl-xL. A, OVAAL expression protects IgR3
and Sk-Mel-28 cells from the cytotoxic effects of ABT-199 (5 µM) and A-1331852 (10 µM) measured at 48 hours using CellTiter-Glo assays. OVAAL expression was depleted using two independent shRNA targeting vectors (sh-OVAAL-1 and -2) and compared with a control shRNA vector. n = 3, mean ± SD; Student's t-test. B, OVAAL expression also protects TRAIL.S and UMI-77.S cells from treatment with ABT-199 (5 µM) and A-1331852 (10 µM). Cell viability assessed after 48 h using CellTiterGlo assays. n = 3, mean ± SD; Student's t-test. 
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